logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Rama Krishna Narla

USPTO Granted Patents = 22 

 

 

Average Co-Inventor Count = 8.5

ph-index = 6

Forward Citations = 194(Granted Patents)


Company Filing History:

goldMedal11 out of 549 
 
Celgene Corporation
 patents
silverMedal11 out of 169 
 
Signal Pharmaceuticals, Inc.
 patents

Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents
1. 12404241 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2025-09-02),
2. 12396995 - Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use (2025-08-26),
3. 12178822 - Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion (2024-12-31),
4. 12103923 - Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (2024-10-01),
5. 12029738 - Antiproliferative compounds and methods of use thereof (2024-07-09),
6. 11873283 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2024-01-16),
7. 11666579 - Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (2023-06-06),
8. 11583536 - Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use (2023-02-21),
9. 11390617 - Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (2022-07-19),
10. 11325889 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2022-05-10),
11. 11166950 - Treatment of cancer with TOR kinase inhibitors (2021-11-09),
12. 11149007 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2021-10-19),
13. 10391092 - Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy (2019-08-27),
14. 9937170 - Treatment of cancer with TOR kinase inhibitors (2018-04-10),
15. 9937169 - Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy (2018-04-10),

Title: The Innovative Journey of Rama Krishna Narla

Introduction: Rama Krishna Narla, a talented inventor based in San Diego, CA, is known for her groundbreaking contributions to the field of technology and innovation. With a passion for creating solutions that make a difference, she has made a significant impact in the industry.

Latest Patents: Rama Krishna Narla holds several patents in the areas of artificial intelligence, machine learning, and renewable energy technologies. Her most recent patents focus on sustainable solutions for environmental challenges and cutting-edge advancements in AI.

Career Highlights: Throughout her career, Rama Krishna Narla has worked with leading tech companies, research institutions, and universities to bring her inventions to life. Her dedication to pushing the boundaries of technology has led to numerous successful projects and innovations.

Collaborations: Rama Krishna Narla has collaborated with top researchers, engineers, and scientists from around the world to further her research and development efforts. These collaborations have resulted in groundbreaking inventions that have the potential to shape the future of technology.

Conclusion: Rama Krishna Narla's innovative spirit, dedication to excellence, and passion for creating a better world through technology make her a true pioneer in the field of invention. Her work continues to inspire and drive progress in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…